A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 4, 2004, Pages 307-315

  Ciccolini, J ^a,b   Mercier, C ^b   Blachon, M F ^a   Favre, R ^b   Durand, A ^a   Lacarelle, B ^a  

^a Fed Pharmacologie Clin Med P   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; HPLC; Pharmacokinetics; Uracil dihydrouracil ratio

Indexed keywords

5 BROMOURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; TRIETHYLAMINE; URACIL;

ACCURACY; ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTRUMENTATION; ROOM TEMPERATURE; TIME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; URACIL;

EID: 4043162680     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00569.x     Document Type: Article

References (42)

1. Longley DB, Harkin DP, Johnston PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nature Review in Cancer, 3, 330-338.
2. Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiology International, 19, 177-189.
3. Di Paolo A, Ibrahim T, Danesi R et al. (2002) Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Therapeutic Drug Monitoring, 24, 588-593.
4. Ridge SA, Sludden J, Wei X et al. (1998) Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. British Journal of Cancer, 77, 497-500.
5. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clinical Cancer Research, 5, 2006-2011.
6. Van Kuilenburg AB, Haasjes J, Richel DJ et al. (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clinical Cancer Research, 6, 4705-4712.
7. Omura K (2003) Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. International Journal of Clinical Oncolology, 8, 132-138.
8. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clinical Cancer Research, 7, 2832-2839.
9. Deporte-Fety R, Picot M, Amiand M et al. (2001) High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. Journal of Chromatography B Biomedical Sciences and Application, 762, 203-209.
10. Tuchman M, Roemeling RV, Hrushesky WA, Sothern RB, O'Dea RF (1989) Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Enzyme, 42, 15-24.
11. Johnson MR, Yan J, Shao L, Albin N, Diasio RB (1997) Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography B Biomedical Sciences and Application, 696, 183-191.
12. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry, 278, 175-184.
13. Takenoue T, Kitayama J, Takei Y et al. (2000) Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Annals in Oncology, 11, 273-279.
14. van Kuilenburg AB, Muller EW, Haasjes J et al. (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clinical Cancer Research, 7, 1149-1153.
15. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R (2003) Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clinical Cancer Research, 9, 3021-3028.
16. Fischer J, Schwab M, Eichelbaum M, Zanger UM (2003) Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genetic Testing, 7, 97-105.
17. Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Research, 50, 197-201.
18. Van Kuilenburg AB, van Lertthe H, Blom MJ, Mul EP, Van Gennip AH (1999) Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. British Journal of Cancer, 79, 620-626.
19. Garg MB, Sevester JC, Sakoff JA, Ackland SP (2002) Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. Journal of Chromatography B Biomedical Sciences and Application, 774, 223-230.
20. Gamelin E, Boisdron-Celle M, Guerin-Meyer V et al. (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. Journal of Clinical Oncology, 17, 1105.
21. Jiang H, Lu J, Ji J (2004) Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. British Journal of Pharmacology, 141, 616-623.
22. Monjanel-Mouterde S, Ciccolini J, Bagarry D, Zonta-David M, Duffaud F, Favre R, Durand A (2003) Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. Journal of Clinical Pharmacy and Therapeutics, 28, 109-116.
23. Diasio RB, Lu Z, Zhang R, Shahinian HS (1995) Fluoropyrimidine catabolism. Cancer Treatment Research, 78, 71-93.
24. Sommadossi JP, Gewirtz DA, Cross DS, Goldman ID, Cano JP, Diasio RB (1985) Modulation of 5-fluorouracil catabolism in isolated rat hepatocytes with enhancement of 5-fluorouracil glucuronide formation. Cancer Research, 45, 116-121.
25. Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Huntingt), 12, 23-27.
26. Salonga D, Danenberg KD, Johnson M et al. (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clinical Cancer Research, 6, 1322-1327.
27. Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? European Journal of Cancer, 36, 37-42.
28. Morsman JM, Sludden J, Ameyaw MM, Githang' A J, Indalo A, Ofori-Adjei D, McLeod HL (2000) Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. British Journal of Clinical Pharmacology, 50, 269-272.
29. Milano G, Etienne MC (1994) Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Research, 14, 2295-2297.
30. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. British Journal of Cancer, 79, 627-630.
31. Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N (2003) Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. American Journal of Clinical Oncology, 26, 103-106.
32. Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics, 3, 485-492.
33. Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML (1994) Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. British Journal of Cancer, 70, 724-728.
34. Escoriaza J, Aldaz A, Calvo E, Giraldez J (1999) Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies. Journal of Chrotnatography B Biomedical Sciences and Application, 736, 97-102.
35. Nassim MA, Shirazi FH, Cripps CM et al. (2002) An HPLC method for the measurement of 5-fluorouracil in human plasma with a low detection limit and a high extraction yield. International Journal of Molecular Medicine, 10, 513-516.
36. Hageboutros A, Rogatko A, Newman EM et al. (1995) Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. Cancer Chemotherapy Pharmacology, 35, 205-212.
37. Jodrell DI, Stewart M, Aird R, Knowles G, Bowman A, Wall L, McLean C (2001) 5-Fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. British Journal of Cancer, 84, 600-603.
38. Etienne MC, Speziale N, Milano G (1993) HPLC of folinic acid diastereoisomers and 5-methyltetrahydrofolate in plasma. Clinical Chemistry, 39, 82-86.
39. Casale F, Canaparo R, Muntoni E et al. (2002) Simultaneous HPLC determination of 5-fluorouracil and its metabolites in plasma of cancer patients. Biomedical Chromatography, 16, 446-452.
40. Zufia L, Aldaz A, Castellanos C, Giraldez J (2003) Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: validation for application in clinical pharmacokinetic studies. Therapeutic Drug Monitoring, 25, 221-228.
41. Geng-Sheng Y, You-Jian H, Hai L, Su L (2003) Relationship of plasma concentration of 5-fluorouracil with toxicity and response in patients with nasopharyngeal carcinoma. Chinese Journal of Cancer, 22, 1349-1351.
42. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM (1978) Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. British Journal of Cancer, 38, 19-24.